ADDED
false --12-31 FY 2025 true true true The Audit Committee of the Board of Directors oversees NRx s cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks.
The cybersecurity stakeholders, including member(s) of management assigned with cybersecurity oversight responsibility and/or third-party consultants providing cyber risk services, brief the Audit Committee on cyber vulnerabilities identified through the risk management process, the effectiveness of NRx s cyber risk management program, and the emerging threat landscape and new cyber risks on at least an annual basis.
This includes updates on NRx's processes to prevent, detect, and mitigate cybersecurity incidents.
The Audit Committee of the Board of Directors oversees NRx s cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks.
The cybersecurity stakeholders, including member(s) of management assigned with cybersecurity oversight responsibility and/or third-party consultants providing cyber risk services, brief the Audit Committee on cyber vulnerabilities identified through the risk management process, the effectiveness of NRx s cyber risk management program, and the emerging threat landscape and new cyber risks on at least an annual basis.
This includes updates on NRx's processes to prevent, detect, and mitigate cybersecurity incidents.
The Audit Committee of the Board of Directors oversees NRx s cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks.
The cybersecurity stakeholders, including member(s) of management assigned with cybersecurity oversight responsibility and/or third-party consultants providing cyber risk services, brief the Audit Committee on cyber vulnerabilities identified through the risk management process, the effectiveness of NRx s cyber risk management program, and the emerging threat landscape and new cyber risks on at least an annual basis.
This includes updates on NRx's processes to prevent, detect, and mitigate cybersecurity incidents.
The Audit Committee of the Board of Directors oversees NRx s cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks.
REMOVED
As of March 14, 2025, the registrant had 16,915,647 shares of common stock outstanding.
(Nasdaq: NRXP) ( NRX or the Company ) is a clinical-stage bio-pharmaceutical company which develops and will distribute, through its wholly-owned operating subsidiary, NeuroRx, Inc.
( NeuroRx ), novel therapeutics for the treatment of central nervous system disorders including suicidal depression, chronic pain, and post-traumatic stress disorder ( PTSD ) and now schizophrenia.
All of our current drug development activities are focused drugs that modulate on the N-methyl-D-aspartate ( NMDA ) receptor in the brain and nervous system, a neurochemical pathway that has been disclosed in detail in our annual filings.
The Company has two lead drug candidates that are expected to be submitted by year end for Food and Drug Administration ("FDA") approval with anticipated FDA decision dates under the Prescription Drug User Fee Act ( PDUFA ) by the end of June 2025: NRX-101, an oral fixed dose combination of D-cycloserine and lurasidone and NRX-100, a preservative-free formulation of ketamine for intravenous infusion.
( HOPE ), a medical care delivery organization focused on interventional psychiatric treatment of the above conditions with NMDA-targeted and other psychedelic drugs, neuromodulatory devices, such as Transcranial Magnetic Stimulation ( TMS ), digital therapeutics, and medication management.
NeuroRx is organized as a traditional research and development ("R D") company, whereas HOPE is organized as a medical care delivery company intended to own and/or operate clinics that serve patients with suicidal depression, PTSD, and other serious Central Nervous System (CNS) disorders.
The 2024 fiscal year marked a period of both expansion and change for NRx.
Throughout this time, the Company implemented a restructuring of its leadership to address challenges related to capital formation, clinical trial enrollment, and corporate development.
These efforts led to measurable achievements in 2024 and positioned the Company for growth and the achievement of our development objectives in 2025.